Antigen Neutralization

Human Immunoglobulin G

Immunologic Deficiency Syndromes

<section class="Section" data-sectioncode="34089-3"><a name="s49"></a><a name="section-10"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">GAMUNEX-C is a ready-to-use sterile, non-pyrogenic solution of human immune globulin protein for intravenous and subcutaneous (PI indication only) administration. GAMUNEX-C is clear to opalescent, and colorless to pale yellow. GAMUNEX-C consists of 9%–11% protein in 0.16–0.24 M glycine. Not less than 98% of the protein has the electrophoretic mobility of gamma globulin. The main component of GAMUNEX-C is IgG (≥ 98%) with a sub-class distribution of IgG<span class="Sub">1</span>, IgG<span class="Sub">2</span>, IgG<span class="Sub">3</span> and IgG<span class="Sub">4</span> of approximately 62.8%, 29.7%, 4.8% and 2.7% respectively. The distribution of IgG subclasses is similar to that found in normal serum.</p><p>GAMUNEX-C contains trace levels of fragments, IgA (average 0.046 mg/mL), and IgM. GAMUNEX-C doses of 1 g/kg correspond to a glycine dose of 0.15 g/kg. While toxic effects of glycine administration have been reported, the doses and rates of administration were 3–4 fold greater than those for GAMUNEX-C. In another study it was demonstrated that intravenous bolus doses of 0.44 g/kg glycine were not associated with serious adverse effects.(<a href="#s60">21</a>) Caprylate is a saturated medium-chain (C8) fatty acid of plant origin. Medium chain fatty acids are considered to be essentially non-toxic. Human subjects receiving medium chain fatty acids parenterally have tolerated doses of 3.0 to 9.0 g/kg/day for periods of several months without adverse effects.(<a href="#s60">22</a>) Residual caprylate concentrations in the final container are no more than 0.216 g/L (1.3 mmol/L). The measured buffer capacity is 35 mEq/L (0.35 mEq/g protein) and the osmolality is 258 mOsmol/kg solvent, which is close to physiological osmolality (285-295 mOsmol/kg). A dose of 1 g/kg body weight therefore represents an acid load of 0.35 mEq/kg body weight. The total buffering capacity of whole blood in a normal individual is 45–50 mEq/L of blood, or 3.6 mEq/kg body weight. Thus, the acid load delivered with a dose of 1 g/kg of GAMUNEX-C would be neutralized by the buffering capacity of whole blood alone, even if the dose was infused instantaneously. The pH of GAMUNEX-C is 4.0–4.5. GAMUNEX-C contains no preservative. GAMUNEX-C is not made with natural rubber latex.</p><p>GAMUNEX-C is made from large pools of human plasma by a combination of cold ethanol fractionation, caprylate precipitation and filtration, and anion-exchange chromatography. Isotonicity is achieved by the addition of glycine. GAMUNEX-C is incubated in the final container (at the low pH of 4.0–4.3). The product is intended for intravenous administration and may be administered subcutaneously in treatment of PI.</p><p>The capacity of the manufacturing process to remove and/or inactivate enveloped and non-enveloped viruses has been validated by laboratory spiking studies on a scaled down process model, using the following enveloped and non-enveloped viruses: human immunodeficiency virus, type I (HIV-1) as the relevant virus for HIV-1 and HIV–2; bovine viral diarrhea virus (BVDV) as a model for hepatitis C virus; pseudorabies virus (PRV) as a model for large enveloped DNA viruses (e.g., herpes viruses); Reovirus type 3 (Reo) as a model for non-enveloped viruses and for its resistance to physical and chemical inactivation; hepatitis A virus (HAV) as relevant non-enveloped virus, and porcine parvovirus (PPV) as a model for human parvovirus B19.(<a href="#s60">23</a>)</p><p>Overall virus reduction was calculated only from steps that were mechanistically independent from each other and truly additive. In addition, each step was verified to provide robust virus reduction across the production range for key operating parameters.</p><table border="0" cellpadding="4" cellspacing="0" width="100%"><caption><span>Table 9: Log<span class="Sub">10</span> Virus Reduction </span></caption><colgroup><col/><col/><col/><col/><col/><col/><col/></colgroup><tfoot><tr><td align="left" colspan="7"><dl class="Footnote"><dt><a href="#footnote-reference-12" name="footnote-12">*</a></dt><dd>C/I - Interference by caprylate precluded determination of virus reduction for this step. Although removal of viruses is likely to occur at the caprylate precipitation/depth filtration step, BVDV is the only enveloped virus for which reduction is claimed. The presence of caprylate prevents detection of other, less resistant enveloped viruses and therefore their removal cannot be assessed.</dd><dt><a href="#footnote-reference-13" name="footnote-13">†</a></dt><dd>NA - Not Applicable: This step has no effect on non-enveloped viruses.</dd><dt><a href="#footnote-reference-14" name="footnote-14">‡</a></dt><dd>Some mechanistic overlap occurs between depth filtration and other steps. Therefore, Grifols Therapeutics LLC has chosen to exclude this step from the global virus reduction calculations.</dd><dt><a href="#footnote-reference-15" name="footnote-15">§</a></dt><dd>CAP - The presence of caprylate in the process at this step prevents detection of enveloped viruses, and their removal cannot be assessed.</dd><dt><a href="#footnote-reference-16" name="footnote-16">¶</a></dt><dd>M/I - Interference by the process intermediate matrix precluded determination of virus removal capacity for this step.</dd><dt><a href="#footnote-reference-17" name="footnote-17">#</a></dt><dd>Sum of reduction factors greater than or equal to 1 log<span class="Sub">10</span>.</dd></dl></td></tr></tfoot><tbody class="Headless"><tr class="First"><td align="center" class="Botrule Lrule Rrule Toprule" rowspan="3" valign="bottom">Process Step</td><td align="center" class="Botrule Lrule Rrule Toprule" colspan="6" valign="bottom">Log<span class="Sub">10</span> Virus   Reduction</td></tr><tr><td align="center" class="Botrule Lrule Rrule Toprule" colspan="3" valign="bottom">Enveloped Viruses</td><td align="center" class="Botrule Lrule Rrule Toprule" colspan="3" valign="bottom">Non-enveloped Viruses</td></tr><tr><td align="center" class="Botrule Lrule Rrule Toprule" valign="bottom">HIV</td><td align="center" class="Botrule Lrule Rrule Toprule" valign="bottom">PRV</td><td align="center" class="Botrule Lrule Rrule Toprule" valign="bottom">BVDV</td><td align="center" class="Botrule Lrule Rrule Toprule" valign="bottom">Reo</td><td align="center" class="Botrule Lrule Rrule Toprule" valign="bottom">HAV</td><td align="center" class="Botrule Lrule Rrule Toprule" valign="bottom">PPV</td></tr><tr><td class="Botrule Lrule Rrule Toprule">Caprylate   Precipitation/Depth Filtration</td><td align="center" class="Botrule Lrule Rrule Toprule">C/I<a class="Sup" href="#footnote-12" name="footnote-reference-12">*</a></td><td align="center" class="Botrule Lrule Rrule Toprule">C/I<a class="Sup" href="#footnote-12">*</a></td><td align="center" class="Botrule Lrule Rrule Toprule">2.7</td><td align="center" class="Botrule Lrule Rrule Toprule">≥ 3.5</td><td align="center" class="Botrule Lrule Rrule Toprule">≥ 3.6</td><td align="center" class="Botrule Lrule Rrule Toprule">4.0</td></tr><tr><td class="Botrule Lrule Rrule Toprule">Caprylate   Incubation</td><td align="center" class="Botrule Lrule Rrule Toprule">≥ 4.5</td><td align="center" class="Botrule Lrule Rrule Toprule">≥ 4.6</td><td align="center" class="Botrule Lrule Rrule Toprule">≥ 4.5</td><td align="center" class="Botrule Lrule Rrule Toprule">NA<a class="Sup" href="#footnote-13" name="footnote-reference-13">†</a></td><td align="center" class="Botrule Lrule Rrule Toprule">NA<a class="Sup" href="#footnote-13">†</a></td><td align="center" class="Botrule Lrule Rrule Toprule">NA<a class="Sup" href="#footnote-13">†</a></td></tr><tr><td class="Botrule Lrule Rrule Toprule">Depth   Filtration<a class="Sup" href="#footnote-14" name="footnote-reference-14">‡</a></td><td align="center" class="Botrule Lrule Rrule Toprule">CAP<a class="Sup" href="#footnote-15" name="footnote-reference-15">§</a></td><td align="center" class="Botrule Lrule Rrule Toprule">CAP<a class="Sup" href="#footnote-15">§</a></td><td align="center" class="Botrule Lrule Rrule Toprule">CAP<a class="Sup" href="#footnote-15">§</a></td><td align="center" class="Botrule Lrule Rrule Toprule">≥ 4.3</td><td align="center" class="Botrule Lrule Rrule Toprule">≥ 2.0</td><td align="center" class="Botrule Lrule Rrule Toprule">3.3</td></tr><tr><td class="Botrule Lrule Rrule Toprule">Column   Chromatography</td><td align="center" class="Botrule Lrule Rrule Toprule">≥ 3.0</td><td align="center" class="Botrule Lrule Rrule Toprule">≥ 3.3</td><td align="center" class="Botrule Lrule Rrule Toprule">4.0</td><td align="center" class="Botrule Lrule Rrule Toprule">≥ 4.0</td><td align="center" class="Botrule Lrule Rrule Toprule">≥ 1.4</td><td align="center" class="Botrule Lrule Rrule Toprule">4.2</td></tr><tr><td class="Botrule Lrule Rrule Toprule">Nanofiltration</td><td align="center" class="Botrule Lrule Rrule Toprule">≥ 3.7</td><td align="center" class="Botrule Lrule Rrule Toprule">M/I<a class="Sup" href="#footnote-16" name="footnote-reference-16">¶</a></td><td align="center" class="Botrule Lrule Rrule Toprule">≥ 4.1</td><td align="center" class="Botrule Lrule Rrule Toprule">≥ 1.8</td><td align="center" class="Botrule Lrule Rrule Toprule">M/I<a class="Sup" href="#footnote-16">¶</a></td><td align="center" class="Botrule Lrule Rrule Toprule">&lt; 1.0</td></tr><tr><td class="Botrule Lrule Rrule Toprule">Low   pH Incubation</td><td align="center" class="Botrule Lrule Rrule Toprule">≥ 6.5</td><td align="center" class="Botrule Lrule Rrule Toprule">≥ 4.3</td><td align="center" class="Botrule Lrule Rrule Toprule">≥ 5.1</td><td align="center" class="Botrule Lrule Rrule Toprule">NA<a class="Sup" href="#footnote-13">†</a></td><td align="center" class="Botrule Lrule Rrule Toprule">NA<a class="Sup" href="#footnote-13">†</a></td><td align="center" class="Botrule Lrule Rrule Toprule">NA<a class="Sup" href="#footnote-13">†</a></td></tr><tr class="Last"><td class="Botrule Lrule Rrule Toprule">Global   Reduction<a class="Sup" href="#footnote-17" name="footnote-reference-17">#</a></td><td align="center" class="Botrule Lrule Rrule Toprule">≥ 17.7</td><td align="center" class="Botrule Lrule Rrule Toprule">≥ 12.2</td><td align="center" class="Botrule Lrule Rrule Toprule">≥ 20.4</td><td align="center" class="Botrule Lrule Rrule Toprule">≥ 9.3</td><td align="center" class="Botrule Lrule Rrule Toprule">≥ 5.0</td><td align="center" class="Botrule Lrule Rrule Toprule">8.2</td></tr></tbody></table><p>Additionally, the manufacturing process was investigated for its capacity to decrease the infectivity of an experimental agent of transmissible spongiform encephalopathy (TSE), considered as a model for the vCJD and CJD agents.(<a href="#s60">23</a>)</p><p>Several of the individual production steps in the GAMUNEX-C manufacturing process have been shown to decrease TSE infectivity of that experimental model agent. TSE reduction steps include two depth filtrations (in sequence, a total of ≥ 6.6 log<span class="Sub">10</span>).  These studies provide reasonable assurance that low levels of CJD/vCJD agent infectivity, if present in the starting material, would be removed.</p></section>

Gamunex-C

immunoglobulin G, human

50 ML immunoglobulin G, human 100 MG/ML Injection

100 ML immunoglobulin G, human 100 MG/ML Injection

10 ML immunoglobulin G, human 100 MG/ML Injection

25 ML immunoglobulin G, human 100 MG/ML Injection

200 ML immunoglobulin G, human 100 MG/ML Injection

400 ML immunoglobulin G, human 100 MG/ML Injection

50 ML immunoglobulin G, human 100 MG/ML Injection [Gamunex]

10 ML immunoglobulin G, human 100 MG/ML Injection [Gamunex]

25 ML immunoglobulin G, human 100 MG/ML Injection [Gamunex]

100 ML immunoglobulin G, human 100 MG/ML Injection [Gamunex]

200 ML immunoglobulin G, human 100 MG/ML Injection [Gamunex]

400 ML immunoglobulin G, human 100 MG/ML Injection [Gamunex]

Gamunex

immunoglobulin G

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information

Medication Guide 

Submit MSL Request 

Pharmacy List 

Billing & Coding Guide 

Coverage Authorization Request 

Coverage Authorization Appeals 

Letter of Medical Necessity 

Formulary Exception Letter 

Other HCP Resources: PIDD

Other HCP Resources: CIDP

About Gamunex-C: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

About Gamunex-C: Primary Immunodeficiency Disease (PIDD)

Enroll in Patient Savings Program: CIDP & PIDD 

Gamunex-C Patient Assistance Program: CIDP & PIDD 

Comprehensive Support Program: All Indications 

Patient Stories 

FAQs: CIDP

Patient Resources: CIDP & PIDD

Instructions for Use: Idiopathic Thrombocytopenic Purpura (ITP)

Instructions for Use: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Instructions For Use: Primary Immunodeficiency Disease (PIDD)